Conservative treatment to slow deterioration of renal function: Evidence-based recommendations

被引:13
作者
Burgess, E [1 ]
机构
[1] Univ Calgary, Dept Med, Calgary, AB, Canada
关键词
progressive renal disease; glomerulonephritis; blood pressure; renoprotection; protein diets; malnutrition;
D O I
10.1046/j.1523-1755.1999.07003.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Despite current specific therapy, progressive deterioration of renal function in patients with primary glomerulonephritis occurs. Nonspecific renoprotective interventions that have been studied include blood pressure control, antihypertensive medications, and protein-restricted diets. To prepare this article, a MEDLINE search was conducted, followed by secondary and tertiary searches. Research papers were assessed for level of evidence, and graded recommendations were formulated. Protein-restricted diets (to 0.4 to 0.6 g/kg/day) are not recommended for all patients with reduced renal function (grade A). Very low-protein diets of 0.4 g/kg/day should be considered for patients with severe renal dysfunction (serum creatinine of more than 350 mu mol/liter; grade A). However, there are concerns about recommending these diets for all patients because of the potential for long-term negative outcomes such as nutritional deficiencies. Target blood pressure for persons with proteinuria of more than 1 g/day should be less than 125/75 mm Hg [mean arterial pressure (MAP) < 92 mm Hg; grade C]. For persons with proteinuria of less than 1 g/day, the target blood pressure should be approximately MAP 98 mm Hg (less than 130/80; grade C). Angiotensin-converting enzyme inhibitor (ACEI) therapy is recommended in preference to placebo, conventional, or P-blocker therapy for renoprotection (grade A). ACEI therapy cannot be recommended above calcium channel blockers in patients with nondiabetic renal disease (grade A).
引用
收藏
页码:S17 / S25
页数:9
相关论文
共 44 条
[31]   LONG-TERM BENEFICIAL-EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION IN PATIENTS WITH NEPHROTIC PROTEINURIA [J].
PRAGA, M ;
HERNANDEZ, E ;
MONTOYO, C ;
ANDRES, A ;
RUILOPE, LM ;
RODICIO, JL .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 20 (03) :240-248
[32]  
PRATA MM, 1994, CLIN NEPHROL, V41, P277
[33]  
Rayner BL, 1996, CLIN NEPHROL, V46, P219
[34]   Understanding the nature of renal disease progression [J].
Remuzzi, G ;
Ruggenenti, P ;
Benigni, A .
KIDNEY INTERNATIONAL, 1997, 51 (01) :2-15
[35]  
ROSMAN JB, 1984, LANCET, V2, P1291
[36]  
ROSMAN JB, 1989, KIDNEY INT, V36, pS96
[37]  
Ruggenenti P, 1997, LANCET, V349, P1857
[38]   Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial [J].
Ruggenenti, P ;
Perna, A ;
Gherardi, G ;
Gaspari, F ;
Benini, R ;
Remuzzi, G .
LANCET, 1998, 352 (9136) :1252-1256
[39]   STRICT BLOOD-PRESSURE CONTROL AND PROGRESSION OF RENAL-DISEASE IN HYPERTENSIVE NEPHROSCLEROSIS [J].
TOTO, RD ;
MITCHELL, HC ;
SMITH, RD ;
LEE, HC ;
MCINTIRE, D ;
PETTINGER, WA .
KIDNEY INTERNATIONAL, 1995, 48 (03) :851-859
[40]   LOVASTATIN THERAPY IN NEPHROTIC HYPERLIPIDEMIA - EFFECTS ON LIPOPROTEIN METABOLISM [J].
VEGA, GL ;
GRUNDY, SM .
KIDNEY INTERNATIONAL, 1988, 33 (06) :1160-1168